Skip to content

Risk of viral rebound decreases with longer treatment, even with previous failures

Merck hopes for US integrase inhibitor license by October

HIV treatment and displaced populations

Four-year analysis of tenofovir finds “favourable safety profile”

A short course of potent HIV therapy during primary infection may slow longer-term disease progression

WHO issues clarification on pharmacovigilance funding

Oral solution of bevirimat provides encouraging results, maturation inhibitor moves ahead

Maraviroc approval delayed in the US

Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated